Drug Trial Radar · NCT04895722
Evaluation of Co-formulated Pembrolizumab/Quavonlimab (MK-1308A) Versus Other Treatments in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Cancer (CRC) (MK-1308A-008/KEYSTEP-008).
Last checked: Nov 19, 2026Latest source record: Nov 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
302
Actual
Start
Jun 25, 2021
Primary completion
May 21, 2025
Study completion Aug 7, 2026
Sponsor
- Lead sponsor
- Merck Sharp & Dohme LLCMerck & Co. (MRK)
- Sponsor type
- Industry
- First posted
- May 20, 2021
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to assess the efficacy and safety of co-formulated pembrolizumab/quavonlimab versus other treatments in participants with MSI-H or dMMR Metastatic Stage IV Colorectal Cancer.
Conditions
- Colorectal Cancer
Interventions
PembrolizumabBiological
400 mg or 200 mg pembrolizumab administered via IV infusion.
Pembrolizumab/QuavonlimabBiological
Co-formulated pembrolizumab/quavonlimab (400 mg/25 mg) fixed-dose combination (FDC) administered via IV infusion.
Pembrolizumab/FavezelimabBiological
Co-formulated pembrolizumab/favezelimab (200 mg/800 mg) FDC administered via IV infusion
Pembrolizumab/VibostolimabBiological
Co-formulated pembrolizumab/vibostolimab (200 mg/200 mg) FDC administered via IV infusion
MK-4830Biological
800 mg MK-4830 administered via IV infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR)Time frame: Up to approximately 46 months
Locations
109 sites in 22 countries. Site status is shown where the registry gives one.
Mid Florida Cancer Center ( Site 1519)
Orange City, Florida
University Cancer & Blood Center, LLC ( Site 1521)
Athens, Georgia
University of Chicago Medical Center-Medicine - Section of Hematology/Oncology - Gastrointestinal P
Chicago, Illinois
Icahn School of Medicine at Mount Sinai ( Site 1528)
New York, New York
Hematology Oncology Associates of Rockland ( Site 1525)
Nyack, New York
UPMC Hillman Cancer Center ( Site 1516)
Pittsburgh, Pennsylvania
The West Clinic, PLLC dba West Cancer Center ( Site 1576)
Germantown, Tennessee
Vanderbilt University Medical Center-Vanderbilt-Ingram Cancer Center ( Site 1509)
Nashville, Tennessee
UT Southwestern Medical Center ( Site 1551)
Dallas, Texas
Baylor Scott & White Medical Center - Temple-Division of Hematology/Oncology ( Site 1549)
Temple, Texas
Northwest Medical Specialties, PLLC ( Site 1546)
Tacoma, Washington
UZ Brussel ( Site 0105)
Brussels, Bruxelles-Capitale, Region de, Belgium
Cliniques universitaires Saint-Luc-Medical Oncology ( Site 0104)
Brussels, Bruxelles-Capitale, Region de, Belgium
Université Catholique de Louvain-Namur - Centre Hospitalier -Oncology ( Site 0102)
Yvoir, Namur, Belgium
UZ Leuven ( Site 0101)
Leuven, Vlaams-Brabant, Belgium
AZ Delta vzw ( Site 0106)
Roeselare, West-Vlaanderen, Belgium
The Moncton Hospital-Oncology ( Site 0307)
Moncton, New Brunswick, Canada
Sunnybrook Research Institute - Odette Cancer Centre ( Site 0316)
Toronto, Ontario, Canada
McGill University Health Centre-CIM - Oncology ( Site 0306)
Montreal, Quebec, Canada
Instituto de Cancerología ( Site 1610)
Medellín, Antioquia, Colombia
Fundación Colombiana de Cancerología Clínica Vida ( Site 1606)
Medellín, Antioquia, Colombia
Clinica de la Costa S.A.S. ( Site 1608)
Barranquilla, Atlántico, Colombia
Clinica Colsanitas S.A, Sede Clínica Universitaria Colombia ( Site 1611)
Bogotá, Bogota D.C., Colombia
Sociedad De Oncologia Y Hematologia Del Cesar-Oncology ( Site 1601)
Valledupar, Cesar Department, Colombia
Oncomédica S.A.S ( Site 1602)
Montería, Departamento de Córdoba, Colombia
Mediservis del Tolima IPS S.A.S ( Site 1609)
Ibague, Tolima Department, Colombia
CIMCA-Hemato-Oncology ( Site 2101)
San José, Provincia de San José, Costa Rica
Hospital Metropolitano - Sede Lindora-Metropolitano Research Institute Sede Lindora ( Site 2102)
Santa Ana, Provincia de San José, Costa Rica
Rigshospitalet ( Site 1904)
Copenhagen, Capital Region, Denmark
Regionshospitalet Gødstrup ( Site 1901)
Herning, Central Jutland, Denmark
Aalborg Universitetshospital, Syd ( Site 1903)
Aalborg, North Denmark, Denmark
Odense Universitetshospital ( Site 1902)
Odense, Region Syddanmark, Denmark
North Estonia Medical Centre Foundation-Chemotherapy ( Site 2301)
Tallinn, Harju, Estonia
Tartu University Hospital ( Site 2302)
Tartu, Tartu, Estonia
Hôpital Saint Antoine-Oncologie médicale ( Site 0508)
Paris, France
Assistance Publique Hôpitaux de Marseille - Hôpital de la Ti-Service d'Hepato-Gastro-Enterologie et
Marseille, Bouches-du-Rhone, France
Centre Georges François Leclerc ( Site 0506)
Dijon, Cote-d Or, France
CHU Rangueil-Digestive oncology department ( Site 0502)
Toulouse, Haute-Garonne, France
Hopital Claude Huriez - CHU de Lille ( Site 0510)
Lille, Nord, France
Centre Hospitalier Universitaire de Poitiers ( Site 0511)
Poitiers, Vienne, France
Showing 40 of 109 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.